Chimerix (CMRX) reported a loss of $0.39 per share in its second quarter, beating consensus forecast by 12 cents. The company�s revenue for the quarter was $1.84 million, down 55.6% on a year-over-year basis. Revenue missed consensus forecast by $0.14 million.

TG Therapeutics (TGTX) reported a loss of $0.33 per share in its second quarter, missing consensus forecast by 4 cents. The company�s revenue for the quarter was $0.04 million, flat on a year-over-year basis. Revenue was in-line with the consensus forecast.

Flamel Technologies (FLML) reported a loss of $0.02 per share in its second quarter, missing consensus forecast by 8 cents. The company reported revenue of $38.86 million, down 20% on a year-over-year basis. Revenue beat consensus forecast by $6.06 million.

Pfenex (PFNX) reported a loss of $0.43 in its second quarter, beating consensus forecast by 4 cents. The company�s revenue for the quarter was $3.14 million, up 37.1% on a year-over-year basis. Revenue beat consensus forecast by $0.59 million.

Inovio Pharmaceuticals (INO) reported a loss of $0.26 per share in its second quarter, missing consensus forecast by 5 cents. The company�s revenue for the quarter was $6.2 million, up 17.2% on a year-over-year basis. Revenue beat consensus forecast by $1.25 million.

Atara Biotherapeutics (ATRA) reported a loss of $0.66 per share in its second quarter. The company ended the quarter with $294.6 million in cash and investments on its balance sheet.